comprehensive -WSS

comprehensive

author：fashion 2025-08-24 10:14:21 - browse：29

President Biden's White House announced the first 10 medicines that will be up first in its new drug price negotiation program. Anna Moneymaker/Getty Images

WASHINGTON — Medicare on Tuesday announced it will negotiate prices for 10 drugs, including major blood thinners and diabetes medications, in the first round of its negotiation program created in Democrats’ drug pricing reform law.

The drugs include Bristol Myers Squibb’s blood thinner Eliquis, Boehringer Ingelheim and Eli Lilly’s diabetes drug Jardiance, Johnson & Johnson’s blood thinner Xarelto, Merck’s diabetes drug Januvia, AstraZeneca’s diabetes drug Farxiga, Novartis’ heart failure treatment Entresto, Amgen’s rheumatoid arthritis drug Enbrel, Johnson & Johnson and AbbVie’s blood cancer treatment Imbruvica, J&J’s anti-inflammatory medicine Stelara, and Novo Nordisk insulins that go by names including Fiasp and NovoLog.

The new prices will be announced on Sept. 1, 2024, and will go into effect on Jan. 1, 2026. The drugs were chosen from a list of 50 treatments that cost Medicare’s pharmacy drug benefit the most money. The selected medicines cost Medicare more than $50 billion and made up 20% of the Medicare program’s pharmacy drug costs over a one-year period, the Department of Health and Human Services said. (Read more here about the winners and losers of the selection.)

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： ASCO Daily Recap: Safety data from Novartis, survival from Pfizer

explore

WSS

Test for long Covid? Researchers find new clue in blood samples

At ASCO, pharma leaders speak of advances in 'smart bomb' drugs

ASCO: AstraZeneca says CAR

ASCO Daily Recap: Safety data from Novartis, survival from Pfizer

Think you might have Covid

For one rare type of lung cancer, Pfizer pill reduces progression by 81%

knowledge

comprehensive

hotspot

Drug repurposing or repositioning? The language matters

Readout LOUD podcast: Biotech layoffs, stock slump, 2024 preview

State Dept. review finds Biden bears some blame for Afghanistan failures

Innovation in antibiotics is ailing. 'Brain drain' may kill it

Duchenne breakthrough therapy leaves behind pioneering families

Parkinson’s finding may lead to tests and, someday, treatments

Wildfire smoke exposes gaps in outdoor worker protections

AI generated plenty of interest at JPM but not a lot of trust

Peter Hotez and the public health issue of online harassment

Cord blood banking comes at a high cost to babies

focus

How digital therapeutics firms are pivoting after Pear's bankruptcy

Kaiser's Risant Health gobbled up Geisinger. Who is next?

ASCO 2024: 'Reassuring' Corbus data on ADC bladder cancer drug

How digital therapeutics firms are pivoting after Pear's bankruptcy

Eli Lilly, Pfizer, and others want in on the online prescription market

Prior authorization will have to move faster under new Biden rule

explore

knowledge

explore

hotspot